Nurix Therapeutics Inc (NASDAQ:NRIX) price on Thursday, April 18, rose 2.56% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $14.44.
A look at the stock’s price movement, the close in the last trading session was $14.08. The beta value (5-Year monthly) was 2.06. Turning to its 52-week performance, $18.12 and $4.22 were the 52-week high and 52-week low respectively. Overall, NRIX moved 13.34% over the past month.
Nurix Therapeutics Inc’s market cap currently stands at around $856.58 million, with investors looking forward to this quarter’s earnings report slated for Jul 11, 2024 – Jul 15, 2024.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that NRIX is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
NRIX’s current price about -1.26% and 12.28% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 50.52, while 7-day volatility ratio is 8.19% and 9.38% in the 30-day chart. Further, Nurix Therapeutics Inc (NRIX) has a beta value of 2.03, and an average true range (ATR) of 1.36.
If we refocus on Nurix Therapeutics Inc (NASDAQ:NRIX), historical trading data shows that trading volumes averaged 963.34K over the past 3 months. The company’s latest data on shares outstanding shows there are 59.32 million shares.
The 7.90% of Nurix Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 73.46% of the company’s shares. Current price change has pushed the stock 39.92% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NRIX stock continues to rise going into the next quarter.
